<i>Akkermansia muciniphila</i> –derived L-norleucine modulates FABP1-dependent fatty acid transport
Abstract
Fatty acids undergo re-esterification to form triglycerides or are directly oxidized for energy production following absorption. Fatty acid binding protein 1 (FABP1), a key transporter highly expressed in both hepatic and intestinal tissues, directs the metabolic fate of absorbed fatty acids. Although its role in facilitating fatty acid transport and lipogenesis in the liver is well established, the functional mechanisms of intestinal FABP1 remain poorly understood due to the complexity of the intestinal microenvironment. In this study, using animal models with intestinal-specific FABP1 knockout and gut microbiota depletion, we demonstrate that intestinal FABP1 directly facilitates the absorption of dietary fatty acids, and that gut microbiota regulate FABP1-mediated dietary fatty acid absorption through metabolites. Notably, the abundance of Akkermansia muciniphila exhibits an inverse correlation with FABP1-dependent obesity progression in an arachidonic acid-induced model. Supplementation with A. muciniphila markedly alleviates this obese phenotype. Through FABP1 protein-based metabolite enrichment coupled with untargeted metabolomics, we identified L-norleucine as a competitive FABP1 inhibitor despite its smaller molecular size relative to long-chain fatty acids. L-norleucine possesses a hydrophobic alkyl chain structurally analogous to fatty acids and a hydrophilic amino acid moiety, which may explain its binding to FABP1. Critically, L-norleucine constitutes a major metabolite in the gut, which may play an underappreciated role in regulating lipid homeostasis. Collectively, this study uncovers a previously unrecognized gut microbiota–FABP1 axis governing lipid homeostasis, offering therapeutic insights for metabolic disorders.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (18)
Juan Li
Zhengcai Ma
School of Life Sciences, Southwest University
Jinyin Zhang
Engineering Research Center of Coptis Development and Utilization (Ministry of Education), College of Pharmaceutical Sciences, Southwest University
Chunyong Sun
Engineering Research Center of Coptis Development and Utilization (Ministry of Education), College of Pharmaceutical Sciences, Southwest University
Huimin Wu
Engineering Research Center of Coptis Development and Utilization (Ministry of Education), College of Pharmaceutical Sciences, Southwest University
Xiaoduo Li
Department of Clinical Laboratory, AnShun City People’s Hospital
Zheng Li
Huiqing Wang
West China Second Hospital, Sichuan University
Yubin Yang
West China Second Hospital, Sichuan University
Lianchun Shang
Emergency Department, Chongqing Hospital Affiliated to Jiangsu Provincial Hospital of Chinese Medicine
Zhipeng Yang
Engineering Research Center of Coptis Development and Utilization (Ministry of Education), College of Pharmaceutical Sciences, Southwest University
Jianyu Zhu
School of Life Sciences, Southwest University
Jifei Liu
Engineering Research Center of Coptis Development and Utilization (Ministry of Education), College of Pharmaceutical Sciences, Southwest University
Rakia Manzoor
Engineering Research Center of Coptis Development and Utilization (Ministry of Education), College of Pharmaceutical Sciences, Southwest University
Li Tang
Zhongshan Institute for Drug Discovery , ,
Xuegang Li
Engineering Research Center of Coptis Development and Utilization (Ministry of Education), College of Pharmaceutical Sciences, Southwest University
Xiaoli Ye
School of Life Sciences, Southwest University
Hang Ma
Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University